← All trials
NCT02441309
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2014
- Primary completion
- Nov 4, 2016
- Completion date
- Nov 4, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 8
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of OxfordLead sponsor
- National Institute for Health Research, United KingdomCollaborator
- European CommissionCollaborator
- TakedaCollaborator
- University of OxfordOverall official - principal investigator
- University of OxfordCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.